Rise Therapeutics, LLC

[On Demand]
Search General Info
Search Education
Search Partnering Companies

Rise Therapeutics is engaged in discovery, development, GMP manufacturing, and clinical development Live Biotherapeutic Products (LBPs). With our novel Tripartite X (TPX) oral biologics delivery platform that enables us to create functionally directed probiotics, we have the ability to harness traditional biologics treatment strategies to evolve novel oral microbiome-based drugs. Located in Rockville, Maryland, Rise Therapeutics has a current pipeline of four immunologically targeted drug candidates that are poised for Phase 1 clinical development, focused on a range of therapeutic areas including IBD, oncology, autoimmunity, and infectious disease. Rise Therapeutics is in the process of identifying partners and investors to help support clinical proof-of-concept studies for these programs. Moreover, we are leveraging our state-of-the-art GMP manufacturing facility and microbiome product expertise as a sponsor to help advance other early-stage companies via partnership or CDMO models.


 


Rise Therapeutics, LLC is presenting as part of the NIH Innovation Zone.

Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Maryland
Company HQ Country:
United States
Year Founded:
2017
Main Therapeutic Focus:
Lead Product in Development:
R-3750
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
President & CEO
Rise Therapeutics, LLC